Li Lexi, Xie Zhengde, Xu Lili
Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Research Unit of Critical Infection in Children, Chinese Academy of Medical Sciences, Beijing, China.
Front Pediatr. 2024 Aug 29;12:1456250. doi: 10.3389/fped.2024.1456250. eCollection 2024.
Human adenoviruses (HAdVs) are important pathogens responsible for respiratory infections. In children and immunocompromised patients, respiratory infections can cause considerable morbidity and mortality. Currently, there are no approved effective and safe antiviral therapeutics for the clinical treatment of HAdV infections, even those that have undergone preclinical/clinical trials. However, many compounds and molecules with anti-HAdV activity have been explored, and some candidates are undergoing clinical development. Here, we reviewed the reported and efficacies, as well as the therapeutic potential of these antiviral compounds, providing an overview and a summary of the current status of anti-HAdV drug development.
人腺病毒（HAdVs）是引起呼吸道感染的重要病原体。在儿童和免疫功能低下的患者中，呼吸道感染可导致相当高的发病率和死亡率。目前，尚无经批准的有效且安全的抗病毒疗法用于临床治疗HAdV感染，即使是那些已经历临床前/临床试验的疗法。然而，许多具有抗HAdV活性的化合物和分子已被探索，一些候选药物正在进行临床开发。在此，我们综述了这些抗病毒化合物的报道疗效以及治疗潜力，对抗HAdV药物开发的现状进行了概述和总结。
